MedTrace Logo

Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication

NCT05469685 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 914

Last updated 2024-06-13

No results posted yet for this study

Summary

The purpose of this study was to evaluate the Efficacy and Safety of Vonoprazan- amoxicillin dual therapy for Helicobacter Pylori eradication

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Vonoprazan

Potassium-competitive acid blocker

DRUG

Amoxicillin

Antibiotic for H. pylori eradication

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Principal Investigators

  • Zhenyu Zhang · Nanjing First Hospital, Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-08-31
Completion
2023-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05469685 on ClinicalTrials.gov